Hy BioPharma Inc.
This article was originally published in Start Up
Executive Summary
Hy BioPharma is developing hypericin phototherapeutics for cancers and autoimmune disorders. The Israeli/US start-up is also in Phase I/IIb trials for an oral formulation of hypericin for possible use in combination therapy with Temodar for the treatment of glioblastoma.
You may also be interested in...
Start-Up Previews (07/2008)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.
Pharmaxon SA
Pharmaxon aims to control cell mobility to fight disorders of the central nervous system and cancer. For glioblastoma, it has developed a neural cell mobility inhibitor that blocks cell migration in vitro and limits glioblastoma proliferation in animal models.
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix is developing convection-enhanced delivery, a technique that involves infusion under positive pressure of a drug to specific locations of the brain. The leading indication for its CED technology is glioblastoma.